158 related articles for article (PubMed ID: 37231503)
1. Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models.
Rupert C; Dell' Aversana C; Mosca L; Montanaro V; Arcaniolo D; De Sio M; Bilancio A; Altucci L; Palinski W; Pili R; de Nigris F
J Exp Clin Cancer Res; 2023 May; 42(1):134. PubMed ID: 37231503
[TBL] [Abstract][Full Text] [Related]
2. Lysosome purinergic receptor P2X4 regulates neoangiogenesis induced by microvesicles from sarcoma patients.
Palinski W; Monti M; Camerlingo R; Iacobucci I; Bocella S; Pinto F; Iannuzzi C; Mansueto G; Pignatiello S; Fazioli F; Gallo M; Marra L; Cozzolino F; De Chiara A; Pucci P; Bilancio A; de Nigris F
Cell Death Dis; 2021 Aug; 12(9):797. PubMed ID: 34404763
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
4. HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells.
Teng R; Liu Z; Tang H; Zhang W; Chen Y; Xu R; Chen L; Song J; Liu X; Deng H
Redox Biol; 2019 Jun; 24():101218. PubMed ID: 31112866
[TBL] [Abstract][Full Text] [Related]
5. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma.
Lucarelli G; Rutigliano M; Sallustio F; Ribatti D; Giglio A; Lepore Signorile M; Grossi V; Sanese P; Napoli A; Maiorano E; Bianchi C; Perego RA; Ferro M; Ranieri E; Serino G; Bell LN; Ditonno P; Simone C; Battaglia M
Aging (Albany NY); 2018 Dec; 10(12):3957-3985. PubMed ID: 30538212
[TBL] [Abstract][Full Text] [Related]
6. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma.
Gu YR; Kim J; Na JC; Han WK
PLoS One; 2022; 17(6):e0269432. PubMed ID: 35671305
[TBL] [Abstract][Full Text] [Related]
8. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
9. NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.
Kubala JM; Laursen KB; Schreiner R; Williams RM; van der Mijn JC; Crowley MJ; Mongan NP; Nanus DM; Heller DA; Gudas LJ
Cancer Biol Ther; 2023 Dec; 24(1):2170669. PubMed ID: 36722045
[TBL] [Abstract][Full Text] [Related]
10. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma.
Chen SL; Huang QS; Huang YH; Yang X; Yang MM; He YF; Cao Y; Guan XY; Yun JP
Theranostics; 2020; 10(20):9186-9199. PubMed ID: 32802186
[TBL] [Abstract][Full Text] [Related]
11. Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma.
Hu W; Yuan Q; Liu XH; Zhu HC; Lv SQ; Wang XH
Eur J Pharmacol; 2015 Feb; 749():142-50. PubMed ID: 25614335
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage.
Zhu M; Li Y; Zhou Z
Biochem Biophys Res Commun; 2017 Oct; 492(3):373-378. PubMed ID: 28847725
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
Wang X; Cheng Y; Zhu Y; Li H; Ge W; Wu X; Zhao K; Yuan J; Li Z; Jiang S; Han Z; Jiang Q; Wu Q; Liu T; Zhang C; Yu M; Hu Y
Int J Cancer; 2017 Oct; 141(7):1422-1433. PubMed ID: 28656647
[TBL] [Abstract][Full Text] [Related]
14. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
15. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Long Q; Sun J; Lv J; Liang Y; Li H; Li X
Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
[TBL] [Abstract][Full Text] [Related]
16. Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy.
Chen D; Sun X; Zhang X; Cao J
J Biochem Mol Toxicol; 2018 Sep; 32(9):e22195. PubMed ID: 30004155
[TBL] [Abstract][Full Text] [Related]
17. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
Wu G; Wang Q; Xu Y; Li J; Zhang H; Qi G; Xia Q
Cell Death Dis; 2019 May; 10(6):416. PubMed ID: 31138790
[TBL] [Abstract][Full Text] [Related]
18. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
[TBL] [Abstract][Full Text] [Related]
19. Soyasapogenol B exhibits anti-growth and anti-metastatic activities in clear cell renal cell carcinoma.
Wang L; Wang J; Zhao H; Jiang G; Feng X; Sui W; Liu H
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):551-563. PubMed ID: 30607469
[TBL] [Abstract][Full Text] [Related]
20. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
